Introduction {#sec0005}
============

Coronavirus disease 2019 (COVID-19), caused by a novel virus --- the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) --- has now become a pandemic. Currently, more than 200 countries, territories or areas are affected by this novel infectious disease ([@bib0040]). On April 10, 2020, the overall number of confirmed COVID-19 cases was 1 521 252 worldwide, with a mortality rate of 6.1% ([@bib0040]). Given the recent estimates of mortality rate for COVID-19 ([@bib0005]), clinicians should be aware of the risk factors associated with a fatal outcome. The literature reports that an older age, presence of underlying comorbidities (such as hypertension, diabetes, and cardiovascular disease), certain laboratory parameters, and severity of lung abnormalities are associated with an increased risk of mortality in patients with SARS-CoV-2 infection ([@bib0030]; [@bib0035]; [@bib0045]; [@bib0050]). To improve the risk stratification for infected patients, we have introduced in clinical practice a new chest X-ray (CXR) scoring system for quantifying and monitoring the severity of lung abnormalities in patients with COVID-19 ([@bib0015]). This CXR scoring system (named the *Brixia* score) grades lung abnormalities due to COVID-19 on an 18-point severity scale ([@bib0015]). To the best of our knowledge, the predictive value of a CXR scoring system in patients with COVID-19 has not yet been studied. Therefore, this study aimed to investigate the usefulness of our CXR scoring system for predicting the risk of in-hospital mortality in patients with SARS-CoV-2 infection.

Materials and Methods {#sec0010}
=====================

Through a retrospective search on the digital hospital archives between March 4, 2020 and March 24, 2020, all CXR reports including the new scoring system (the *Brixia* score) were retrieved. We enrolled only hospitalized Caucasian patients with COVID-19 (confirmed by real-time polymerase chain reaction) for whom the final outcome (recovery or death) was available. Patients with incomplete information about the presence of underlying comorbidities and immunosuppressive therapies were excluded from the study. For each included patient, only the CXR report with the highest score was considered for analysis. Each frontal chest projection linked to these reports was independently reviewed by a thoracic radiologist (A.B.), with 15 years' experience of thoracic imaging, who reassigned the *Brixia* score. All chest X-rays were performed using portable digital radiography systems.

Notification of this retrospective study was presented to the Institutional Ethical Committee. Given the retrospective design of the study, the need for informed consent was waived.

To investigate significant differences between recovered and dead patients, we selected nine independent variables that were presumed to influence the final outcome ([Table 1](#tbl0005){ref-type="table"} ). These variables were analyzed using chi-square or Mann-Whitney U tests. The significant variables were subsequently included in a multivariable logistic regression model to extract the independent predictive factors for in-hospital mortality. In addition, the predictive power of the model was expressed as area under the curve. *p*-Values of \<0.05 were considered statistically significant.Table 1Association between the final outcome and the selected independent variables.Table 1Independent variablesTotal (302)Final outcome*p-*Value\*Recovery (237)Death (65)Patient age, years67.0 (57.0--77.0)64.0 (54.0--73.3)77.0 (70.5--81.0)\<0.0001Patient sex Male194 (64.2)144 (47.7)50 (16.6)0.0162 Female108 (35.8)93 (30.8)15 (5.0)*Brixia* score8.0 (5.0--11.0)7.0 (4.0--10.0)11.0 (9--13.0)\<0.0001Hypertension Yes154 (51.0)112 (37.1)42 (13.9)0.0133 No148 (49.0)125 (41.4)23 (7.6)Cardiovascular disease Yes126 (41.7)84 (27.8)42 (13.9)\<0.0001 No176 (58.3)153 (50.7)23 (7.6)Diabetes Yes38 (12.6)25 (8.3)13 (4.3)0.0422 No264 (87.4)212 (70.2)52 (17.2)Chronic obstructive/restrictive lung disease Yes44 (14.6)31 (10.3)13 (4.3)0.1620 No258 (85.4)206 (68.2)52 (17.2)Oncological history within the past 5 years Yes56 (18.5)36 (11.9)20 (6.6)0.0043 No246 (81.5)201 (66.6)45 (14.9)T/D inducing immunosupppresion Yes98 (32.5)62 (20.5)36 (11.9)\<0.0001 No204 (67.5)175 (57.9)29 (9.6)[^1]

Results {#sec0015}
=======

We identified 302 Caucasian patients who were hospitalized for COVID-19 ([Table 1](#tbl0005){ref-type="table"}). The relationships between the final outcome and the selected independent variables are summarized in [Table 1](#tbl0005){ref-type="table"}. In the multivariable logistic regression model, only *Brixia* score, patient age, and conditions that induced immunosuppression were independent predictive factors for in-hospital mortality, and were therefore included in the predictive model ([Table 2](#tbl0010){ref-type="table"} ). With regard to immunosuppressive conditions, most patients had advanced renal failure (42%), hematological disorders (20%), or were treated with corticosteroids (18%).Table 2Multivariable logistic regression analysis.Table 2Predictive factorCoefficient*p*-ValueOdds ratio95% CI*Brixia* score0.283\<0.00011.3271.200--1.472Age0.078\<0.00011.0811.046--1.118T/D inducing immunosupppresion0.7450.02782.1061.085--4.087[^2]

According to receiver operating characteristic curve analyses, the optimal cutoff values for *Brixia* score and patient age were 8 points and 71 years, respectively. Three different models that included the *Brixia* score showed excellent predictive power ([Figure 1](#fig0005){ref-type="fig"} ).Figure 1Comparison of receiver operating characteristic (ROC) curves generated using the three risk prediction models. Solid blue line (Model 1): ROC curve obtained using all three predictive factors. Dotted red line (Model 2): ROC curve obtained using *Brixia* score and patient age. Dashed orange line (Model 3): ROC curve obtained using *Brixia* score and immunosuppressive conditions.Figure 1

Discussion {#sec0020}
==========

For our large study cohort, in-hospital mortality was 21.5%, and higher in men than in women. Multivariable analysis showed that only *Brixia* score, patient age, and immunosuppressive conditions were the risk factors strongly associated with in-hospital mortality.

In line with the findings of many authors, our study found that older age and severity of lung abnormalities were associated with poor prognosis in patients with COVID-19 ([@bib0030]; [@bib0035]; [@bib0045]; [@bib0050]). In addition, as reported in another study ([@bib0050]), our results did not confirm the predictive power of underlying comorbidities such as hypertension, cardiovascular disease, diabetes, chronic lung disease, and oncological history.

The currently available data on the impact of immunosuppressive status on mortality in COVID-19 are few, with a limited number of patients, and obtained almost exclusively from Asian patients ([@bib0020]). In our large cohort of adult Caucasian patients, we observed that immunosuppressive conditions significantly increased the risk of in-hospital mortality ([Table 2](#tbl0010){ref-type="table"}). Therefore, we believe that our results will be of great importance and will help clinicians in determining appropriate clinical management by improving risk stratification in infected patients.

The major strength of this study is the large sample size, which comprised only Caucasian patients. Although several studies have investigated the role of CT score in patients with COVID-19 ([@bib0010], [@bib0025], [@bib0045]), this is the first study to assess the effectiveness of a CXR scoring system for predicting in-hospital mortality in infected patients. The main limitations of this study include the retrospective study design and lack of laboratory parameters included in the predictive models (because these data were collected from a limited number of cases).

In conclusion, this study demonstrated for the first time that a high *Brixia* score and at least one other predictive factor --- patient age and conditions that induced immunosuppression --- conferred the highest risk of death due to COVID-19. This information may help clinicians with patient management and treatment planning, and would help them prepare for possible adverse outcomes.
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[^1]: Data are presented as numbers (%) or medians (interquartile range); \**p*-values obtained by Mann--Whitney U test or chi-square test; T/D, therapy or disease.

[^2]: T/D, therapy or disease; CI, confidence interval.
